P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1), is an active efflux membrane transporter that limits oral drug absorption and mediates the biliary and renal excretion of cationic and amphiphilic substrates.

Google

To understand and manage potential drug-drug interactions in COVID-19 treatments, key pharmacological, biochemical, and physiological concepts are classified into the following groups:
- **General Pharmacology**: Pharmacokinetics and pharmacodynamics.
- **Drug Transporters**: Organic Anion Transporters (OAT), Organic Anion Transporting Polypeptides (OATP), Organic Cation Transporters (OCT), and P-glycoprotein (P-gp/MDR1).
- **Intracellular Signaling Pathways**: Janus Kinases (JAK), Signal Transducers and Activators of Transcription (STAT), and Mechanistic Target of Rapamycin (mTOR).
- **Enzymatic Metabolism**: Cytochrome P450 (CYP) enzymes.
- **Cardiac Electrophysiology Risk**: QT prolongation, Torsades de Pointes, and bradycardia.

Classification of Pharmacological and Physiological Concepts in COVID-19 Therapies

Direct Oral Anticoagulants (DOACs) are a class of blood thinners that work by directly blocking a single blood clotting factor (such as Factor Xa or thrombin) to treat or prevent blood clots, commonly used in conditions like deep vein thrombosis and thromboembolism.

Direct Oral Anticoagulants (DOACs)

P-glycoprotein (MDR1) Transporter

The Cytochrome P450 (CYP) superfamily is a major group of enzymes, primarily localized in the liver, that plays a critical role in the metabolic clearance and biotransformation of various drugs and endogenous compounds.

Learn Before

Related